Asset profile
TR-012001
Small molecule
Evidence outlook · no controlled comparison
NCT06212089 · Parkinson Disease
The lead study's design has limits that temper confidence (see the rationale below), and it produced no formal comparison against a control. This tier describes the design, not an outcome.
NCT06212089: The study randomly assigned 12 participants to TR-012001 or placebo and masked participants, but it was single-blind and very small. Because no results are posted, it cannot establish whether the primary safety comparisons were favorable or statistically significant.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
69 competitors in this universe: 9 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 39 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| TR-012001: this drug | Phase 2 | Small molecule | dopamine precursor | ||
| Crexont (IPX203) | Approved | Small molecule | dopamine precursor | ||
| Foslevodopa / Foscarbidopa (Vyalev) | Approved | Small molecule | dopamine precursor | ||
| Inbrija (CVT-301) | Approved | Small molecule | dopamine precursor | ||
| Levodopa-Carbidopa Intestinal Gel (Duopa) | Approved | Small molecule | dopamine precursor | ||
| Parcopa | Approved | Small molecule | dopamine precursor | ||
| Rytary (IPX066) | Approved | Small molecule | dopamine precursor | ||
| ND0612 | Phase 3 | Small molecule | dopamine precursor | ||
| WD-1603 | Phase 2 | Small molecule | dopamine precursor | ||
| Melevodopa / Carbidopa (Sirio) | Phase 1/2 | Small molecule | dopamine precursor | ||
| Amantadine ER (Gocovri / ADS-5102) | Approved | Small molecule | NMDA receptor | ||
| Apomorphine (Apokyn) | Approved | Small molecule | dopamine | ||
| Apomorphine Sublingual Film (Kynmobi) | Approved | Small molecule | dopamine | ||
| Entacapone (Comtess) | Approved | Small molecule | COMT | ||
| Istradefylline (Nourianz) | Approved | Small molecule | adenosine A2A | ||
| Opicapone (Ongentys) | Approved | Small molecule | COMT, PDE4 |
…and 54 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
3 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.